Skip to main content

Table 1 Recipient baseline and clinical characteristics of ex vivo lung perfusion (EVLP) lung transplantations (LTX) and conventional LTx

From: Ten year follow-up of lung transplantations using initially rejected donor lungs after reconditioning using ex vivo lung perfusion

Variables EVLP-LTx (n = 6) Conventional-LTx (n = 15) p-value
Weight (kg) 70.7 ± 19.3 59. 1 ± 7.9 0.060
Height (cm) 170.8 ± 11.8 169.9 ± 10.1 0.862
BMI 24.0 ± 5.3 20.5 ± 3.5 0.088
Male 3 (50%) 6 (40%) 0.523
Age (years) 54.1 ± 10.4 42.6 ± 14.8 0.100
Waiting list (days) 49.0 (7–174) 44 (4–389) 0.785
Pre-op Life support
 Mechanical ventilation 0 (0.00%) 1 (6.66%) 0.714
 ECMO 0 (0.00%) 1 (6.66%) 0.750
Major indication    0.407
 COPD 3 (50.00%) 5 (33.33%)  
 AAT1 1 (16.66%) 0 (0.00%)  
 PH 0 (0.00%) 1 (6.66%)  
 CF 1 (16.66%) 7 (46.66%)  
 PF 1 (16.66%) 1 (6.66%)  
 LAM 0 (0.00%) 1 (6.66%)  
Lab values
 FVC (liters) 2.0 ± 0.4 1.0 ± 0.6 0.540
 FEV1 (liters) 0.8 ± 10.4 54.1 ± 10.4 0.516
 6MWT (%) 39.6 ± 21.4 45.9 ± 25.1 0.600
 P-ALT (μkat/L) 0.41 ± 0.15 0.32 ± 10.4 0.181
 P-AST (μkat/L) 0.46 ± 0.12 0.41 ± 0.11 0.443
 P-creatinine (μmol/L) 64.4 ± 11.5 54.1 ± 15.8 0. 216
Tx-type
 SLTx 0 (0%) 0 (0%)  
 DLTx 6 (100%) 15 (100%)  
 HLTx 0 (0%) 0 (0%)  
 Re-LTx 0 (0%) 0 (0%)  
  1. Data are mean (SD), number (%), or median (range). The numbers are based on patients with available data. COPD, chronic obstructive pulmonary disease; AAT1, Alpha 1-antitrypsin deficiency; PH, pulmonary hypertension; CF, cystic fibrosis; PF, pulmonary fibrosis; LAM, Lymphangioleiomyomatosis; BMI, body-mass index; FVC, forced volume vital capacity; FEV1, forced volume expiratory capacity 1 s; 6MWT, 6-min walking test; AST, aspartate transaminase; ALT, alanine transaminase; SLTx, single-lung transplantation; DLTx, double-lung transplantation; HLTx, heart-lung transplantation; Re-LTx, re-lungtransplantation; ECMO, extracorporeal membrane oxygenation